Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
Cipla Ltd has raised the guidance for the quarterly runrate of its US sales to $235 mln-$240 mln in the coming quarters, as it expects market share gains in niche drugs such as Lanreotide, ramp-up of some more new launches and higher production from facilities in the country. Until now, the company's guidance for US sales was $220 mln-$225 mln, which it has either achieved or exceeded in the last five quarters, including Apr-Jun.
Share this Story:
